Business Context and Reporting Period
This Form 8-K Current Report was filed by Miragen Therapeutics, Inc. (trading symbol: MGEN) on July 2, 2020. The report addresses a specific corporate event regarding the company's listing status on The Nasdaq Stock Market LLC. Note: The request metadata references "Viridian Therapeutics, Inc.," but the filing text explicitly identifies the registrant as Miragen Therapeutics, Inc.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. This report is a notification of a regulatory compliance event rather than a financial performance statement.
Material Changes
- Listing Status: On July 2, 2020, Miragen Therapeutics, Inc. announced it has regained compliance with NASDAQ listing requirements.
- Regulatory Action: The company issued a press release (attached as Exhibit 99.1) confirming the resolution of previous listing deficiencies.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the context of the listing compliance. The document explicitly states that the information furnished, including the attached press release, is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the specific NASDAQ listing requirements that were previously not met and the actions taken to regain compliance.
- Review the attached Exhibit 99.1 (Press Release) for details on the timeline of the compliance process.
- Confirm the company's current stock trading status on The Nasdaq Stock Market LLC.
- Check subsequent filings (e.g., 10-Q or 10-K) for the financial metrics absent in this 8-K.